These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 23941313)

  • 1. Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion.
    David SP; Strong DR; Leventhal AM; Lancaster MA; McGeary JE; Munafò MR; Bergen AW; Swan GE; Benowitz NL; Tyndale RF; Conti DV; Brown RA; Lerman C; Niaura R
    Addiction; 2013 Dec; 108(12):2202-11. PubMed ID: 23941313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The DRD4 exon III VNTR, bupropion, and associations with prospective abstinence.
    Bergen AW; Javitz HS; Su L; He Y; Conti DV; Benowitz NL; Tyndale RF; Lerman C; Swan GE
    Nicotine Tob Res; 2013 Jul; 15(7):1190-200. PubMed ID: 23212438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation.
    David SP; Brown RA; Papandonatos GD; Kahler CW; Lloyd-Richardson EE; Munafò MR; Shields PG; Lerman C; Strong D; McCaffery J; Niaura R
    Nicotine Tob Res; 2007 Aug; 9(8):821-33. PubMed ID: 17654295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine D4 receptor gene variation moderates the efficacy of bupropion for smoking cessation.
    Leventhal AM; David SP; Brightman M; Strong D; McGeary JE; Brown RA; Lloyd-Richardson EE; Munafò M; Uhl GR; Niaura R
    Pharmacogenomics J; 2012 Feb; 12(1):86-92. PubMed ID: 20661272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine transporter polymorphisms are associated with short-term response to smoking cessation treatment.
    O'Gara C; Stapleton J; Sutherland G; Guindalini C; Neale B; Breen G; Ball D
    Pharmacogenet Genomics; 2007 Jan; 17(1):61-7. PubMed ID: 17264803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Catechol-O-methyltransferase (COMT) gene variants predict response to bupropion therapy for tobacco dependence.
    Berrettini WH; Wileyto EP; Epstein L; Restine S; Hawk L; Shields P; Niaura R; Lerman C
    Biol Psychiatry; 2007 Jan; 61(1):111-8. PubMed ID: 16876132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of bupropion and predictors of successful outcome in a sample of French smokers: a randomized placebo-controlled trial.
    Aubin HJ; Lebargy F; Berlin I; Bidaut-Mazel C; Chemali-Hudry J; Lagrue G
    Addiction; 2004 Sep; 99(9):1206-18. PubMed ID: 15317642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of cessation in African American light smokers enrolled in a bupropion clinical trial.
    Faseru B; Nollen NL; Mayo MS; Krebill R; Choi WS; Benowitz NL; Tyndale RF; Okuyemi KS; Ahluwalia JS; Sanderson Cox L
    Addict Behav; 2013 Mar; 38(3):1796-803. PubMed ID: 23254230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association of dopamine pathway gene score, nicotine dependence and smoking cessation in a rural male population of Shandong, China.
    Li S; Wang Q; Pan L; Li H; Yang X; Jiang F; Zhang N; Han M; Jia C
    Am J Addict; 2016 Sep; 25(6):493-8. PubMed ID: 27490263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopaminergic genetic variation moderates the effect of nicotine on cigarette reward.
    Harrell PT; Lin HY; Park JY; Blank MD; Drobes DJ; Evans DE
    Psychopharmacology (Berl); 2016 Jan; 233(2):351-60. PubMed ID: 26497691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multivariate analysis of dopaminergic gene variants as risk factors of heroin dependence.
    Vereczkei A; Demetrovics Z; Szekely A; Sarkozy P; Antal P; Szilagyi A; Sasvari-Szekely M; Barta C
    PLoS One; 2013; 8(6):e66592. PubMed ID: 23840506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A controlled trial of bupropion added to nicotine patch and behavioral therapy for smoking cessation in adults with unipolar depressive disorders.
    Evins AE; Culhane MA; Alpert JE; Pava J; Liese BS; Farabaugh A; Fava M
    J Clin Psychopharmacol; 2008 Dec; 28(6):660-6. PubMed ID: 19011435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial of nicotine replacement therapy (NRT), bupropion and NRT plus bupropion for smoking cessation: effectiveness in clinical practice.
    Stapleton J; West R; Hajek P; Wheeler J; Vangeli E; Abdi Z; O'Gara C; McRobbie H; Humphrey K; Ali R; Strang J; Sutherland G
    Addiction; 2013 Dec; 108(12):2193-201. PubMed ID: 23859696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP2B6 rs2279343 polymorphism is associated with smoking cessation success in bupropion therapy.
    Tomaz PR; Santos JR; Issa JS; Abe TO; Gaya PV; Krieger JE; Pereira AC; Santos PC
    Eur J Clin Pharmacol; 2015 Sep; 71(9):1067-73. PubMed ID: 26153084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bupropion for smoking cessation in African American light smokers: a randomized controlled trial.
    Cox LS; Nollen NL; Mayo MS; Choi WS; Faseru B; Benowitz NL; Tyndale RF; Okuyemi KS; Ahluwalia JS
    J Natl Cancer Inst; 2012 Feb; 104(4):290-8. PubMed ID: 22282543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic variation in the dopamine D4 receptor (DRD4) gene and smoking cessation: follow-up of a randomised clinical trial of transdermal nicotine patch.
    David SP; Munafò MR; Murphy MF; Proctor M; Walton RT; Johnstone EC
    Pharmacogenomics J; 2008 Apr; 8(2):122-8. PubMed ID: 17387332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in food reward following smoking cessation: a pharmacogenetic investigation.
    Lerman C; Berrettini W; Pinto A; Patterson F; Crystal-Mansour S; Wileyto EP; Restine SL; Leonard DG; Shields PG; Epstein LH
    Psychopharmacology (Berl); 2004 Aug; 174(4):571-7. PubMed ID: 15138759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.
    Gonzales D; Rennard SI; Nides M; Oncken C; Azoulay S; Billing CB; Watsky EJ; Gong J; Williams KE; Reeves KR;
    JAMA; 2006 Jul; 296(1):47-55. PubMed ID: 16820546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacotherapy effects on smoking cessation vary with nicotine metabolism gene (CYP2A6).
    Chen LS; Bloom AJ; Baker TB; Smith SS; Piper ME; Martinez M; Saccone N; Hatsukami D; Goate A; Bierut L
    Addiction; 2014 Jan; 109(1):128-137. PubMed ID: 24033696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.
    Jorenby DE; Hays JT; Rigotti NA; Azoulay S; Watsky EJ; Williams KE; Billing CB; Gong J; Reeves KR;
    JAMA; 2006 Jul; 296(1):56-63. PubMed ID: 16820547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.